Daily Sepsis Research Analysis
Analyzed 54 papers and selected 3 impactful papers.
Summary
Today’s top sepsis research spans the care continuum: a nationwide cohort links early‑onset neonatal infection to long‑term cognitive impairment; a pilot randomized study shows plasminogen-containing plasma restores fibrinolysis in sepsis-induced DIC; and an AI-driven pipeline identifies ombuin, an ALDH2-activating inhibitor of M1 macrophage polarization, improving survival in murine sepsis.
Research Themes
- Long-term neurodevelopment after early-onset neonatal sepsis
- Restoring fibrinolysis in sepsis-induced DIC
- AI-driven immunomodulatory therapeutics targeting macrophage polarization
Selected Articles
1. Early-onset neonatal infection and cognitive impairment: a nationwide cohort study.
In a nationwide cohort of 993,363 near- to term-born children, early-onset sepsis and meningitis were associated with significantly increased risks of intellectual disability and special educational needs up to long-term follow-up. Associations were robust in sibling-matched and culture-positive subgroup analyses, with meningitis conferring the highest risk.
Impact: This large, methodologically rigorous cohort quantifies the long-term neurocognitive burden after early-onset neonatal infection, informing surveillance and early intervention strategies.
Clinical Implications: Children with early-onset sepsis/meningitis warrant structured neurodevelopmental follow-up and early educational support planning. Findings support preventive perinatal strategies and timely treatment to reduce invasive infection.
Key Findings
- Early-onset sepsis was associated with increased risk of intellectual disability (aHR 2.24, 95% CI 1.93–2.59).
- Early-onset sepsis increased special educational needs (aHR 1.49, 95% CI 1.40–1.59).
- Early-onset meningitis had even higher risks (intellectual disability IRR 7.75; special educational needs aHR 2.95).
- Associations persisted in sibling-matched analyses and culture-positive subgroups.
Methodological Strengths
- Nationwide, register-based cohort with very large sample size (n=993,363) and long follow-up.
- Multiple robustness checks including sibling-matched and culture-positive subgroup analyses.
Limitations
- Observational design susceptible to residual confounding and misclassification.
- Relatively few culture-confirmed infections may limit precision in subgroup analyses.
Future Directions: Evaluate targeted neurodevelopmental screening and interventions in survivors of early-onset infection and assess the impact of contemporary perinatal sepsis prevention strategies.
OBJECTIVE: To study the effect of early-onset neonatal infection on long-term cognitive impairment including intellectual disability and special educational needs. METHODS: A nationwide register-based cohort study was conducted including near-term to term children born between 1997 and 2013 with follow-up until 2021. Early-onset infection was defined as an invasive bacterial infection within the first week after birth defined by either physician-assigned diagnoses or bacterial pathogens cultured from blood or cerebrospinal fluid. Outcomes included diagnoses of intellectual disability and special educational needs. Associations were estimated by adjusted HRs (aHR) or unadjusted incidence rate ratios (IRR), when exposures and outcomes were rare. Additional analyses were conducted, including sibling-matched analyses and subgroup analyses considering only children with culture-positive infection. RESULTS: Among 993 363 children, 8267 (0.8%) had sepsis and 152 (<0.1%) had meningitis. Of these, 260 had culture-positive sepsis and 31 had culture-positive meningitis. Early-onset sepsis was associated with an increased risk of intellectual disability (aHR: 2.24, 95% CI 1.93 to 2.59) and special educational needs (aHR: 1.49, 95% CI 1.40 to 1.59). Early-onset meningitis was associated with higher risks of both intellectual disability (IRR: 7.75, 95% CI 3.34 to 15.27) and special educational needs (aHR: 2.95, 95% CI 2.06 to 4.22). The associations remained consistent across multiple additional analyses, including sibling-matched analyses and subgroup analyses limited to culture-positive infections. CONCLUSIONS: Early-onset neonatal infection in near-term to term children was associated with an increased risk of long-term cognitive impairment including both intellectual disability and special educational needs.
2. Plasminogen supplementation reverses fibrinolytic insufficiency in sepsis-induced disseminated intravascular coagulation: a pilot study.
In a pilot randomized study of 60 patients with sepsis-induced coagulopathy, pathogen-inactivated plasma containing plasminogen (OctaplasLG) increased functional plasminogen and improved plasmin generation versus saline, with a non-significant trend toward lower mortality. Parallel murine DIC experiments corroborated restoration of fibrinolytic capacity after plasminogen supplementation.
Impact: This work provides mechanistic and translational evidence that restoring fibrinolysis via plasminogen supplementation may counteract sepsis-induced DIC.
Clinical Implications: Phenotyping fibrinolytic insufficiency may identify candidates for plasminogen-enriched plasma as adjunctive therapy in sepsis-induced DIC, warranting adequately powered outcome trials and safety assessments.
Key Findings
- OctaplasLG increased functional plasminogen (+46 nM vs. -84 nM; p < 0.05) and improved plasmin generation versus saline.
- No significant changes occurred in plasmin–antiplasmin complexes, PAI-1, or tPA levels post-infusion.
- A non-significant mortality reduction trend was observed (42.3% vs. 60.0%).
- In septic DIC mice, plasminogen supplementation restored both plasminogen levels and plasmin generation.
Methodological Strengths
- Randomized comparison with predefined mechanistic endpoints in humans.
- Parallel validation in a murine septic DIC model.
Limitations
- Pilot sample size with limited power for clinical outcomes.
- Plasma product contains multiple proteins, potentially confounding plasminogen-specific effects.
Future Directions: Conduct multicenter, adequately powered RCTs to test patient-centered outcomes, refine dosing/timing, and identify fibrinolysis phenotypes predictive of benefit.
PURPOSE: Sepsis-induced disseminated intravascular coagulation (DIC) is characterized by impaired fibrinolysis, partly due to neutrophil elastase-mediated plasminogen degradation. We aimed to evaluate whether plasminogen supplementation could restore fibrinolytic capacity in patients with sepsis-induced coagulopathy and in a murine model of septic DIC. METHODS: 60 patients with sepsis-induced coagulopathy were randomized to receive 12 mL/kg of placebo (NaCl 0.9%) or OctaplasLG®, a pathogen-inactivated pooled human plasma containing 2 µM plasminogen. Pre- and post-infusion levels of functional plasminogen, plasmin generation, and fibrinolysis markers (plasmin-antiplasmin complexes, plasminogen activator inhibitor-1, and tissue-type plasminogen activator) were measured. In parallel, in a sepsis-induced DIC model, transgenic TM RESULTS: In patients, baseline plasminogen and plasmin generation were significantly lower than in healthy controls. OctaplasLG® significantly increased functional plasminogen (+ 46 nM [-96; 118] vs. -84 [-180; 27] nM, p < 0.05) and improved plasmin generation (0.12 [-0.25; 1.27] vs. -0.36 [-1.58; 0.12] fmol, p < 0.05). No changes were observed in plasmin-antiplasmin, plasminogen activator inhibitor-1, or tissue-type plasminogen activator levels. A non-significant trend toward reduced mortality was noted in patients receiving OctaplasLG® (42.3% vs. 60.0%). Septic DIC-mice also exhibited reduced functional plasminogen (100 [66-126] vs. 295 [268-343] nM) and impaired plasmin generation (1.8 [1.4-2.1] vs. 3.0 [2.8-3.3] fmol, p < 0.05), which were restored after plasminogen supplementation (plasminogen: 346 [287; 360] nM; plasmin generation: 4.1 [3.7; 5.5] fmol). CONCLUSION: Plasminogen supplementation restores fibrinolytic capacity, supporting its therapeutic potential in sepsis-induced DIC.
3. AI-driven pipeline discovers ombuin as a novel M1 macrophage polarization inhibitor for sepsis treatment.
An AI pipeline (TVAE) screened 5,516 natural products and identified ombuin, which inhibited LPS-induced M1 macrophage polarization and cytokine release in vitro and improved survival in CLP-induced murine sepsis. Proteomic target deconvolution showed ombuin activates ALDH2, dampening NF-κB signaling.
Impact: Demonstrates an efficient AI-to-bench workflow yielding a mechanistically defined immunomodulator that improves survival in sepsis models.
Clinical Implications: While preclinical, the ALDH2–NF-κB axis and macrophage polarization emerge as tractable targets; ombuin is a lead for optimization toward early-phase clinical testing.
Key Findings
- TVAE screened 5,516 natural products and prioritized ombuin as an M1 polarization inhibitor.
- Ombuin (10 μM) suppressed LPS-induced M1 polarization and IL-6/TNF-α release in vitro.
- In CLP-induced sepsis, ombuin (15, 45 mg/kg, i.p.) improved survival and reduced systemic inflammation.
- LiP-MS indicated ombuin binds and activates ALDH2, suppressing NF-κB p65 nuclear translocation.
Methodological Strengths
- Integrated AI-based screening with experimental validation across in vitro and in vivo systems.
- Target deconvolution with LiP-MS linking phenotype to ALDH2 activation and NF-κB modulation.
Limitations
- Preclinical study; human safety, PK/PD, and optimal dosing are unknown.
- Single species/disease model may limit generalizability; off-target effects require evaluation.
Future Directions: Medicinal chemistry optimization, comprehensive toxicology, and translational studies to validate ALDH2 activation as a therapeutic mechanism in human sepsis.
Sepsis is a life-threatening condition driven by dysregulated immune responses to infection with excessive M1 macrophage polarization-driven cytokine storm which plays a key role in the early progression of sepsis. Targeting macrophage polarization represents a promising therapeutic strategy to improve sepsis outcomes. Conventional drug discovery is hampered by high costs, long timelines and low success rates, posing significant challenges to the identification of novel M1 polarization inhibitors. In this study we constructed a novel transformer-variational autoencoder (TVAE) that integrated complementary molecular fingerprints (extended-connectivity fingerprints, ECFP; molecular ACCess system keys, MACCS keys; 4-point pharmacophore fingerprints, 4-PP) into probabilistic latent distributions to screen for M1-polarization inhibitors. From 5516 natural products, TVAE combined with experimental validation identified ombuin as the top candidate. In vitro, ombuin (10 μM) potently suppressed LPS-induced M1 polarization and pro-inflammatory cytokine (IL-6, TNF-α) release. In cecal ligation and puncture (CLP)-induced mouse sepsis model, administration of ombuin (15, 45 mg/kg, i.p.) significantly improved survival and ameliorated systemic inflammation by modulating the balance of M1/M2 macrophage polarization. By performing LiP-MS assay, we demonstrated that ombuin bound to and activated aldehyde dehydrogenase 2 (ALDH2), thereby suppressing NF-κB p65 nuclear translocation, a key event underlying NF-κB-driven M1 macrophage polarization. Collectively, our AI-driven pipeline efficiently discovers immunomodulatory agents and positions ombuin as a promising lead for sepsis therapy.